Skip to main content
Hunan Hansen Pharmaceutical Co.,Ltd. logo

Hunan Hansen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 002412 ISIN · CNE100000PK2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002412

About Hunan Hansen Pharmaceutical Co.,Ltd.

https://www.hansenzy.com

Hunan Hansen Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio encompasses a diverse range of chemical drugs and traditional Chinese medicine (TCM) preparations. Key therapeutic areas include cardiovascular health, digestive system disorders, and anti-infective treatments. Notable products include Simotang Oral Liquid, a widely recognized TCM for gastrointestinal motility, and various chemical formulations such as Simvastatin tablets. The company operates modern production facilities compliant with Good Manufacturing Practice (GMP) standards and maintains a robust R&D infrastructure focused on drug innovation and formulation optimization. Its operations integrate traditional medicinal knowledge with contemporary pharmacological technology to serve healthcare markets through a comprehensive supply chain and clinical research initiatives.

Recent filings

Filing Released Lang Actions
湖南启元律师事务所关于湖南汉森制药股份有限公司2025 年度股东会的法律意见书
Regulatory Filings Classification · 86% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, voting procedures, and results of the 2025 annual shareholders’ meeting. It does not itself constitute the company’s formal voting results announcement, nor is it a proxy statement, AGM presentation, or any financial report. Instead, it is a compliance/legal filing (an opinion on the validity of the AGM). Such third-party legal opinions are best classified under the general regulatory/filing category. Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-19 Chinese
关于选举职工代表董事的公告
Board/Management Information Classification · 98% confidence The document is an official announcement from the company’s board regarding the election of an employee representative director, i.e., a change in the board of directors. This fits the Board/Management Information category.
2026-05-19 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is an official announcement of the 2025 annual shareholders meeting resolutions of Hunan Hansen Pharmaceutical Co., Ltd., detailing meeting attendance and complete vote tallies for each proposal. It is clearly a Declaration of Voting Results from a general meeting, matching the DVA category.
2026-05-19 Chinese
提名委员会议事规则（2025年10月）
Governance Information Classification · 95% confidence The document is titled '湖南汉森制药股份有限公司提名委员会议事规则' which translates to 'Nomination Committee Meeting Rules' of Hunan Hansen Pharmaceutical Co., Ltd. It details the rules, responsibilities, composition, and procedures of the company's nomination committee, which is a governance body responsible for nominating directors and senior management. The content focuses on governance structure and internal rules rather than financial data, audit information, or announcements. There is no indication of financial results, voting results, or report publication. The document is a governance-related internal rules document, fitting the category of Governance Information (CGR). The document length is 2765 characters, which is relatively short but contains substantive governance rules, not just an announcement or summary. Therefore, the appropriate classification is CGR with high confidence.
2025-10-27 Chinese
董事及高级管理人员所持本公司股份及其变动管理办法（2025年10月）
Governance Information Classification · 95% confidence The document is titled as a management policy regarding the holdings and changes in shares by the company's directors and senior management. It details rules, procedures, and disclosure requirements for share transactions by these insiders. It is a governance-related document focused on internal rules and compliance concerning shareholding by management. There is no indication that this is a report of financial results, an announcement of voting results, or a regulatory filing of financial data. It is not a report publication announcement or a certification. The content fits the category of Governance Information, which covers internal rules, board structure, and governance practices related to company management and their shareholdings.
2025-10-27 Chinese
审计委员会议事规则（2025年10月）
Governance Information Classification · 95% confidence The document is titled '审计委员会议事规则' which translates to 'Audit Committee Meeting Rules'. It details the internal rules, composition, responsibilities, meeting procedures, and other governance-related aspects of the audit committee within the company. There is no financial data, audit report, or financial statements included. The document is a governance framework document rather than a report or announcement of financial results or audit findings. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.